Healthcare provider profile · identity verified

Brenna Gibbons

Nurse Practitioner · CLEVELAND, OH · NPI 1083286041

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	338	125
Amlodipine Besylate	Amlodipine Besylate	265	101
Lisinopril	Lisinopril	260	97
Metformin Hcl	Metformin Hcl	168	60
Rosuvastatin Calcium	Rosuvastatin Calcium	145	56
Levothyroxine Sodium	Levothyroxine Sodium	135	52
Metoprolol Succinate	Metoprolol Succinate	120	43
Albuterol Sulfate Hfa	Albuterol Sulfate	119	39
Losartan Potassium	Losartan Potassium	115	47
Simvastatin	Simvastatin	97	31
Pantoprazole Sodium	Pantoprazole Sodium	96	40
Hydrochlorothiazide	Hydrochlorothiazide	92	34
Furosemide	Furosemide	82	31
Omeprazole	Omeprazole	75	26
Metoprolol Tartrate	Metoprolol Tartrate	72	29
Gabapentin	Gabapentin	65	31
Tamsulosin Hcl	Tamsulosin Hcl	63	29
Carvedilol	Carvedilol	59	23
Eliquis	Apixaban	59	29
Sertraline Hcl	Sertraline Hcl	57	22
Jardiance	Empagliflozin	48	18
Trazodone Hcl	Trazodone Hcl	48	18
Doxazosin Mesylate	Doxazosin Mesylate	47	14
Warfarin Sodium	Warfarin Sodium	46	17
Montelukast Sodium	Montelukast Sodium	45	14
Ezetimibe	Ezetimibe	44	17
Potassium Chloride	Potassium Chloride	44	13
Fluticasone Propionate	Fluticasone Propionate	40	18
Methylprednisolone	Methylprednisolone	40	39
Pravastatin Sodium	Pravastatin Sodium	36	16
Allopurinol	Allopurinol	35	17
Clopidogrel	Clopidogrel Bisulfate	33	14
Ozempic	Semaglutide	32	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Glimepiride	Glimepiride	30	suppressed
Spironolactone	Spironolactone	30	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	suppressed
Nitroglycerin	Nitroglycerin	28	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	12
Tramadol Hcl	Tramadol Hcl	27	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Atenolol	Atenolol	24	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Finasteride	Finasteride	23	suppressed
Breo Ellipta	Fluticasone/Vilanterol	22	suppressed
Digoxin	Digoxin	22	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	22	suppressed
Prednisone	Prednisone	22	11
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Alendronate Sodium	Alendronate Sodium	19	suppressed
Duloxetine Hcl	Duloxetine Hcl	19	suppressed
Famotidine	Famotidine	19	suppressed
Meloxicam	Meloxicam	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	18	suppressed
Alprazolam	Alprazolam	17	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Linzess	Linaclotide	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Midodrine Hcl	Midodrine Hcl	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Novolin R Flexpen	Insulin Regular, Human	14	suppressed
Ramipril	Ramipril	14	suppressed
Glipizide	Glipizide	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	12	suppressed
Pulmicort Flexhaler	Budesonide	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Topiramate	Topiramate	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Jantoven	Warfarin Sodium	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error